Overview

Liposomal Bupivacaine (Exparel) in Sarcomas

Status:
Terminated
Trial end date:
2019-06-11
Target enrollment:
Participant gender:
Summary
The purpose of this research is to study a medication called liposomal bupivacaine (EXPAREL®). Study doctors want to see if it is safe, if it can reduce pain after surgery, and the study doctor want to study its use after the removal a soft tissue tumor called a sarcoma
Phase:
Early Phase 1
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Bupivacaine